SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HUTCHMED Highlights Phase III SANOVO Data at ESMO Congress

HUTCHMED said ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population. The data were presented at the ESMO Congress 2026.

HCM

Related stories